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Abstract
Importance—Detailed, nationally-representative data describing high-risk populations and 
circumstances involved in insulin-related hypoglycemia and errors (IHEs) can inform approaches 
to individualizing glycemic targets.
Objective—Describe U.S. burden, rates, and characteristics of emergency department (ED) visits 
and emergent hospitalizations for IHEs.
Design—Nationally-representative, public health surveillance of adverse drug events and a 
national, household survey of insulin use.
Setting—National Electronic Injury Surveillance System—Cooperative Adverse Drug Event 
Surveillance (NEISS-CADES), 2007–2011 and National Health Interview Survey (NHIS), 2007–
2011.
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Participants—Insulin-treated patients seeking ED care.
Main outcome(s) and Measures—Estimated annual numbers and estimated annual rates of 
ED visits and hospitalizations for IHEs among insulin-treated patients with diabetes.
Results—Based on 8,100 cases, an estimated 97,648 (95% confidence interval [CI], 64,410–
130,887) ED visits for IHEs occurred annually; almost one-third (29.3% [CI, 21.8%–36.8%]) 
resulted in hospitalization. Severe neurologic sequelae were documented in an estimated 60.6% 
(CI, 51.3%–69.9%) of ED visits for IHEs, and glycemic levels ≤50 mg/dL were recorded in over 
one-half of cases (53.4%). Insulin-treated patients aged ≥80 years were more than twice as likely 
to visit the ED (rate ratio, 2.5; CI, 1.5–4.3) and nearly five times as likely to be subsequently 
hospitalized (rate ratio, 4.9; CI, 2.6–9.1) for IHEs than those aged 45–64 years. The most 
commonly-identified IHE precipitants were reduced food intake and administration of the wrong 
insulin product.
Conclusions and Relevance—Rates of ED visits and subsequent hospitalizations for IHEs 
were highest in patients aged ≥80 years; the risks of hypoglycemic sequelae in this age group 
should be considered in decisions to prescribe and intensify insulin. Meal-planning and insulin 
product mix-up misadventures are important targets for hypoglycemia prevention efforts.
Insulin is a cornerstone of Type 1 diabetes mellitus (T1DM) treatment and is increasingly 
introduced early in the treatment course for patients with Type 2 DM (T2DM), who account 
for 90% to 95% of new DM cases annually.1 Over the last decade, the number of U.S. 
patients with insulin-treated DM rose 50%; one-third of patients with diabetes currently use 
insulin,2 and in 2012, insulin was estimated to cost the U.S. healthcare system 
approximately $6 billion.3 Tight glycemic control with insulin has been associated with 
reductions in disease complications among patients with T1DM,4 but has been increasingly 
associated with harms among patients with T2DM.5–7 Insulin remains one of the most 
challenging and limiting aspects of DM medical management owing to complexities in 
dosing and administration, as well as need for routine monitoring of blood glucose (BG) and 
food intake to avoid potentially fatal hypoglycemia.8 The risk of insulin-related 
hypoglycemia is an important consideration when choosing among treatment options and 
individualizing glycemic targets, particularly in patients for whom benefits of intensive 
control may not be as likely realized.9, 10
We used recent, nationally-representative data to estimate the burden and rates of 
insulinrelated hypoglycemia and errors (IHEs) resulting in emergency department (ED) 
visits and subsequent hospitalizations, and identify high-risk groups and precipitating factors 
for IHEs.
METHODS
DATA SOURCES & COLLECTION METHODS
Numerator Data—We estimated the numbers of U.S. ED visits and hospitalizations for 
IHEs based on data from the 63 hospitals participating in the National Electronic Injury 
Surveillance System–Cooperative Adverse Drug Event Surveillance (NEISS-CADES) 
project, a stable, nationally-representative, size-stratified probability sample of hospitals 
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(excluding psychiatric and penal institutions) in the U.S. and its territories with a minimum 
of 6 beds and a 24-hour emergency department (Figure 1).11 As described elsewhere,12 
trained coders at each hospital review clinical records of every ED visit to identify 
physician-diagnosed adverse drug events (ADEs), and report up to two medications 
implicated in the adverse event as well as any concomitant medications documented in the 
medical record. Coders also record narrative descriptions of the ADE, including preceding 
events, physician diagnosis, clinical and laboratory testing, treatment administered by 
emergency medical services (EMS) or ED staff, and discharge disposition.
Denominator Data—We estimated the numbers of U.S. patients who reported having DM 
and using insulin or oral diabetes agents from the National Health Interview Survey (NHIS), 
a multistage cluster sample of non-institutionalized civilian households (Figure 1).13
Institutional Review Board Approval—NEISS-CADES data collection is considered a 
public health surveillance activity by federal human subjects oversight bodies and does not 
require human subject review or institutional review board (IRB) approval.14 NHIS data 
collection is approved by the IRB at the National Center for Health Statistics, Centers for 
Disease Control and Prevention, Hyattsville, MD. No approval is necessary for analyses of 
deidentified survey data.15
DEFINITIONS
ED visits for IHEs included visits to any NEISS-CADES ED from January 1, 2007 through 
December 31, 2011 in which there was clinician documentation of (1) insulin-related 
clinically relevant hypoglycemia (BG <70 mg/dL, diagnosis of “hypoglycemia”, or 
treatment for hypoglycemia), or (2) “insulin overdose” or “insulin reaction”, or (3) an error 
in insulin use (e.g., administration of the wrong insulin dose). ED visits for allergic 
reactions, local effects (e.g., injection site pain), non-hypoglycemic effects (e.g., “headache” 
alone) and accidental needlesticks were excluded. Definitions of other variables, including 
IHE location, clinical presentation, BG levels, hypoglycemia treatments, diabetes therapy, 
and precipitating factors are provided in eTable 1.
Prevalence of self-reported diabetes from January 1, 2007 through December 31, 2011 was 
estimated from the number of NHIS respondents who answered “Yes” to the question, 
“Have you ever been told by a doctor or health professional that you have diabetes or sugar 
diabetes?”.16–18 For those ≥ 18 years of age, prevalence of insulin-treated diabetes was 
estimated via the number of NHIS respondents who answered “Yes” to the question, “Are 
you now taking insulin?”. For those <18 years of age, this question is not asked; thus, 
prevalence of diagnosed diabetes was used as a proxy for insulin treatment. Insulin-treated 
patients were considered to be treated with both insulin and oral diabetes agent(s) if they 
also answered “Yes” to the question, “Are you now taking diabetic pills to lower your blood 
sugar?”.
STATISTICAL ANALYSIS
Each NEISS-CADES record is accompanied by a sample weight based on inverse 
probability of selection, adjusted for non-response and hospital non-participation, and post-
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stratified to account for changes in the number of U.S. ED visits each year. Each NHIS 
record is accompanied by a sample weight based on non-zero probability of selection, with 
design, ratio, non-response and post-stratification adjustments; post-stratification adjustment 
is made relative to census control totals for the number of U.S. civilian, non-institutionalized 
individuals.19
National estimates and proportions of ED visits and hospitalizations for IHEs and national 
estimates of patients with diabetes using insulin alone or in combination with oral diabetes 
agents, with corresponding 95% confidence intervals (CIs) were calculated using the 
SURVEYMEANS procedure in SAS (version 9.3, SAS Institute, Cary, NC) to account for 
the sample weights and complex sample designs. Estimates and their corresponding CIs 
derived from 2007–2011 NEISS-CADES and NHIS data were divided by 5 to obtain 
average annual estimates and CIs. Estimates based on small numbers of cases (<20) or with 
a coefficient of variation greater than 30% were considered statistically unstable and are 
noted in the tables. National estimates were calculated for variables with completed 
documentation (≥90% of cases); case-based analysis was used for remaining variables.
To estimate rates of ED visits and hospitalizations for IHEs in relation to insulin exposure, 
we divided (NEISS-CADES-derived) estimates of ED visits or hospitalizations for IHEs by 
(NHIS-derived) estimates of insulin-treated patients. A similar approach was used to 
estimate the rates of IHEs by age and sex. Accompanying CIs were calculated accounting 
for variability in both numerator and denominator estimates, and assuming statistical 
independence (as these components were derived from separate surveys).20 These rate 
estimates were then used to calculate rate ratios (RRs) of ED visits and hospitalizations for 
IHEs associated with different patient groups. Estimated CIs for RRs were calculated using 
an initial logarithmic transformation and incorporated the estimated variances of the 
numerators and denominators of both component rate estimates, which were assumed to be 
independent across patient populations.21
RESULTS
NUMBERS OF ED VISITS
Based on 8,100 NEISS-CADES surveillance cases, an estimated 97,648 (CI, 64,410–
130,887) ED visits for IHEs occurred annually between 2007 and 2011 (Table 1), 
accounting for 9.2% (CI, 6.7%–11.8%) of ED visits for all ADEs during this period. Among 
the very elderly (≥80 years of age), ED visits for IHEs accounted for 12.4% (CI, 8.9%–
16.0%) of ED visits for all ADEs. The estimated median age of patients who presented to 
EDs for IHEs was 60 years for patients treated with insulin alone and 67 years for patients 
treated with insulin and at least one oral diabetes agent. An estimated 50.4% (CI, 46.4%–
54.3%) of ED visits for IHEs occurred among males. Among adults (≥18 years of age), at 
least one oral diabetes agent was documented in addition to insulin in an estimated 17.1% 
(CI, 13.3%–20.8%) of ED visits for IHEs (Table 2).
Geller et al. Page 4













RATES OF ED VISITS AND HOSPITALIZATIONS
Patients ≥80 years of age had the highest estimated rate of ED visits for IHEs (34.9 per 
1,000 insulin-treated patients with diabetes; CI, 20.5–49.3), followed by patients 18–44 
years of age (24.3 per 1,000; CI, 15.0–33.6). When all patients ≥65 years of age are 
considered, the estimated rate was 20.5 per 1000 (CI, 13.2–27.8). Insulin-treated patients 
≥80 years of age were more than twice as likely to seek ED evaluation for IHEs than those 
65–79 years of age (RR, 2.1; CI, 1.3–3.7) and those 45–64 years of age (RR, 2.5; CI, 1.5–
4.3) (Table 2). Patients ≥80 years of age were also almost five times as likely to be 
hospitalized for IHEs than those 45–64 years of age (RR, 4.9; CI, 2.6.–9.1). No significant 
differences in the rates of ED visits (RR, 1.0; CI, 0.6–1.6) or hospitalizations (RR, 1.2; CI, 
0.6–2.1) for IHEs were identified between female and male patients. Overall, the rate of ED 
visits for IHEs among patients ≥18 years of age treated with insulin only was five times that 
of patients treated with insulin and at least one oral diabetes agent (RR, 5.3; CI, 3.2–8.8); the 
RR decreased as patient age increased (Table 2).
SPECIFIC INSULIN AND CONCOMITANT ORAL AGENTS
In an estimated 22.9% of ED visits for IHEs, more than one type of insulin product was 
documented in the medical record (Table 3). Long-acting (32.9%) and rapid-acting (26.4%) 
products were the most commonly-documented insulin product types (eTable 2). Metformin 
and sulfonylureas were the most commonly-documented concomitant oral diabetes agents, 
identified in 50.9% (CI, 47.6%–54.2%) and 39.2% (CI, 34.8%–43.6%) of estimated ED 
visits for IHEs where an oral diabetes agent was documented, respectively.
IHE CHARACTERISTICS – NATIONAL ESTIMATES
Hypoglycemia was documented in an estimated 95.4% of ED visits for IHEs, and severe 
neurologic sequelae (i.e., hypoglycemia-associated shock, loss of consciousness, or seizure; 
hypoglycemia-associated injury or fall; or hypoglycemia-associated altered mental status) 
were documented in an estimated 60.6% (CI, 51.3%–69.9%) of ED visits (Table 3). Almost 
one-third (29.3%) of estimated ED visits for IHEs required admission, transfer to another 
facility, or observation admission; observation admissions comprised 2.1% (CI, 0.9%–3.3%) 
of estimated ED visits.
IHE CHARACTERISTICS – CASE-BASED ANALYSIS
In most cases (53.3%), IHEs occurred in a home setting (eTable 2). Use of an insulin pump 
was documented in 6.1% of cases. Over one-half (53.4%) of cases involved a BG level ≤50 
mg/dL. Intravenous dextrose 50% was the most common EMS/ED treatment administered 
(50.8% of cases).
PRECIPITATING FACTORS
Precipitating factors for ED visits for IHEs were documented in an estimated 20.8% (CI, 
14.8%–26.9%) of ED visits. When documented, almost one-half (45.9%) involved meal-
related misadventures (e.g., neglecting to eat shortly after taking a rapid-acting insulin, not 
adjusting insulin regimen in the presence of reduced caloric intake) (Table 4). Taking the 
wrong insulin product was documented in an estimated 22.1% of ED visits for IHEs with 
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documented precipitants, and taking the wrong dose or confusing dosing units was 
documented in an estimated 12.2% of ED visits with documented precipitants. Among ED 
visits for IHEs where taking the wrong insulin was documented, the most commonly 
reported error was mixing up long-acting and rapid-acting insulin products. In an estimated 
52.3% (CI, 42.5%–62.0%) of these ED visits, patients reported an intent to take a long-
acting insulin product (e.g., detemir, glargine), but took a rapid-acting one (e.g., aspart, 
lispro) instead. The proportion hospitalized did not differ among ED visits where an IHE 
precipitant was documented (20.7%; CI, 15.9%–25.4%) compared with ED visits without an 
IHE precipitant documented (31.6%; CI, 22.9%–40.2%).
DISCUSSION
Insulin is an important component of diabetes treatment, but remains complex to manage 
and poses serious risk of hypoglycemia.22 These national data quantify the burden and 
severity of IHEs, identify patient groups at higher risk for these events, and describe 
precipitating factors that could be targeted by prevention efforts.
Nearly 100,000 ED visits and 30,000 hospitalizations annually for IHEs demonstrate the 
high frequency and significant health impact of these adverse events. Based on prior cost 
estimates of ED visits for hypoglycemia,23 ED visits for IHEs may have cost well over $600 
million during the 5-year study period. Direct comparisons of our findings to those of 
previous studies are limited by differences in study methodologies. One study estimated 
40,700 ED visits for insulin and other diabetes agent-related adverse events in 2010 using 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
diagnosis codes for poisoning (962.3) or adverse effects due to insulin or other diabetes 
agents (E932.3);24 however, cause-of-injury codes such as these have low sensitivity for 
identifying many ADEs.25 Another study estimated that 316,000 visits for hypoglycemia 
were made to U.S. EDs in 2007 based on reporting of hypoglycemia as the first-listed 
diagnosis and diabetes as a secondary diagnosis;26 however, this analysis lacked information 
on insulin use and could not exclude hypoglycemia episodes related to other factors (e.g., 
alcohol use, occult infection).
The IHEs we identified were serious events, with BG levels ≤50 mg/dL in over half of cases 
and severe neurologic manifestations in almost two-thirds of cases. We have previously 
found insulin to be one of the most commonly implicated drugs in adverse events treated in 
EDs.27 Based on the more recent data in this study, IHEs accounted for 1 out of every 8 
estimated ED visits for ADEs among the very elderly (≥80 years of age), who sought ED 
evaluation and were hospitalized for IHEs at rates two and five times higher than those 45–
64 years of age, respectively. Other studies have found that Medicare beneficiaries ≥85 
years of age are twice as likely to experience a hypoglycemia-related hospitalization 
compared with those 65–74 years of age,28 and that re-hospitalizations and mortality are 
more frequent among older adults (≥66 years of age) with at least one episode of 
hospitalized hypoglycemia.29
Although there are notable exceptions,30–33 until very recently, most diabetes treatment 
guidelines, quality metrics, and pay-for-performance measures placed little emphasis on 
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hypoglycemia risk factors such as advanced age, limited life expectancy, or frailty.34 The 
higher rates of ED visits and hospitalizations for IHEs among older insulin-treated patients 
with diabetes suggest that individualizing glycemic targets by balancing hypoglycemia risks 
with long-term benefits of glycemic control is appropriate.22, 35–37 Updated guidelines and 
treatment recommendations are now advising glycemic targets be relaxed for patients with 
advanced age, high risk of hypoglycemia or shorter life expectancy.22, 35, 38, 39 For example, 
the American Geriatrics Society has advocated for avoiding adding medications to achieve 
tight hemoglobin A1c control in most adults ≥65 years of age.40, 41 Tighter glycemic control 
may continue to be appropriate for functional and cognitively intact elderly patients with 
diabetes who have longer life expectancy and for whom intensive insulin therapy can be 
managed safely;22, 35 however, the high frequency and severity of ED visits for IHEs 
suggest careful consideration of hypoglycemic sequelae and a cautious approach when 
deciding whether to start or intensify insulin treatment among older adults, especially the 
very elderly.
Adoption of a patient-centered approach to setting glycemic targets9, 10, 42–44 also requires 
development of healthcare quality metrics which recognize targets based on individual 
patients’ clinical profiles and preferences.33 Although current National Quality Forum-
endorsed quality metrics do not yet incorporate variation in A1c target levels based on 
hypoglycemia risk,45, 46 new quality measures might allow for considerations of 
hypoglycemia risks along with long-term benefits of glycemic control.47
Enhanced prevention efforts should target commonly-identified IHE precipitants.48 
Although meal-planning is a well-recognized component of diabetes self-management 
education,49, 50 the most commonly-documented IHE precipitant in this study was meal-
related misadventure, suggesting further emphasis on meal-planning in diabetes patient 
education efforts may be needed. Reducing the frequency of missed meals and improving 
patients’ competency in adjusting insulin regimens when food intake is reduced may require 
both content review (e.g., reviewing patients’ understanding of dietetic needs in relation to 
BG levels) and simulation (e.g., patients demonstrating how they would manage insulin with 
a missed meal or reduced food intake scenario).48, 51
Administration of the wrong insulin product (e.g., rapid-acting vs. long-acting agents) was 
the second most commonly-documented IHE precipitant. The number of U.S. poison control 
center calls for insulin-related unintentional therapeutic errors increased in the last decade, 
but the frequency of specific errors, such as using the wrong insulin product, has not been 
described.52, 53 Recently, insulin packaging has become more distinguishable;54 however, 
mix-ups continue55 and further product type distinctions (e.g., using packaging color or 
texture) might be explored for reducing medication errors. Also, diabetes self-management 
education might emphasize distinguishing insulin types, minimizing mix-ups (e.g., storing 
rapid-acting and long-acting agents in different locations), and correctly timing insulin 
administration.54, 56
This study’s findings should be interpreted in the context of the limitations of public health 
surveillance data. First, these data likely underestimate the total burden of hypoglycemic 
events as hypoglycemia, although a frequent cause of EMS calls,57–61 is most often cared 
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for outside of the ED setting.62 Patients who have hypoglycemia unawareness63, 64 and 
whose episodes may not result in EMS or ED care are not counted. Patients who died en 
route to or in the ED are also not counted. Second, since information on past medical history 
is limited in the ED medical record, the contributions of risk factors for hypoglycemia such 
as DM type, intensity and duration of insulin therapy, glycemic control, concomitant 
medications, and comorbidities were not assessed. Third, the specific insulin brand, 
formulation, and delivery system were not always documented, which limited the ability to 
assess differences in ED visits and hospitalizations for IHEs across specific insulin products. 
Similarly, we did not make detailed comparisons between patients treated with insulin alone 
and those treated with insulin and oral diabetes agent(s) because documentation of 
concurrent oral diabetes therapy may have been incomplete. Nonetheless, it is notable that 
across all adult age groups the rate of estimated ED visits for IHEs was consistently lower 
among those treated with concurrent oral diabetes therapy, perhaps suggesting concurrent 
use of long-acting insulin products, with less risk for hypoglycemia.65 Fourth, BG levels 
were not specified in approximately one-third of cases; nevertheless, over half of cases still 
had documented BG ≤50 mg/dL. Other indicators of the seriousness of these events included 
almost 60,000 estimated ED visits for IHEs with severe neurologic sequelae and almost 
30,000 estimated ED visits resulting in hospitalization.
Insulin-related hypoglycemia and errors are clinically significant causes of ED visits and 
hospitalizations for ADEs, particularly among very elderly patients with diabetes. Reducing 
ED visits for adverse events related to injectable diabetes agents has been recognized as a 
national priority for improving the health of Americans in a new Healthy People 2020 
goal.66 Reaching this goal will likely require balancing glycemic risks in vulnerable older 
patient populations and augmenting prevention efforts targeted at key IHE precipitants, such 
as meal-related misadventures and insulin product mix-ups. Healthcare quality metrics 
should evolve based on the most current glycemic control guidelines, and the impact of 
changing guidelines, quality metrics, and prevention strategies should be evaluated via 
ongoing national surveillance.22, 35, 67–69
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Data sources and Descriptions.
Abbreviations: ED, emergency department; EMS, emergency medical services; NEISS-
CADES, National Electronic Injury Surveillance System–Cooperative Adverse Drug Event 
Surveillance;11, 12 NHIS, National Health Interview Survey.13
a NHIS Core Questionnaire (Sample Adult and Sample Child components).
b Responses from persons who answered they had "borderline" diabetes are treated as 
unknown. For female respondents, this question begins with the phrase, “Other than during 
pregnancy”.
c For persons <18 years of age, these questions are not asked; for this age group, prevalence 
of diagnosed diabetes was used as a proxy for national estimates of insulin treatment.
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Table 3
Number of Cases and Estimates of Emergency Department Visits for Insulin-related Hypoglycemia and 
Errors, by Case Characteristics—United States, 2007–2011a
Case Characteristics
ED Visits for IHEs
Cases Annual National Estimate
No. % 95% ConfidenceInterval
Number of Insulin Productsb
1 6,149 77.1 71.3 – 83.0
2 1,892 22.3 16.5 – 28.0
≥3 59 0.6 0.3 – 0.9
Other Diabetes Agentsc
Biguanide (metformin) 705 8.5 6.7 – 10.4
Sulfonylurea 500 6.6 4.7 – 8.5
Thiazolidinedione (glitazones) 312 3.6 2.4 – 4.7
Dipeptidyl peptidase-4 inhibitor (gliptins) 82 1.3 0.6 – 2.0
Other / unspecified oral agent 73 0.9 0.5 – 1.4
Exenatide, liraglutide, pramlintide 21 0.2 0.1 – 0.4
Clinical Presentation of Event
Hypoglycemia 7,760 95.4 93.6 – 97.2
  With shock, loss of consciousness, or seizure 1,846 23.2 15.5 – 31.0
  With fall or injury 491 5.1 3.7 – 6.4
  With altered mental status 2,535 32.3 20.6 – 44.0
  With other neurologic sequelae 416 4.8 3.3 – 6.3
  With presyncope/syncope 398 4.4 3.3 – 5.6
  With other sequelae 439 5.6 3.8 – 7.4
  Without specific sequelae documented 1,635 20.0 13.4 – 26.6
No hypoglycemia documentedd 340 4.6 2.8 – 6.4
Discharge Dispositione
Admitted, transferred, or held for observation 2,447 29.3 21.8 – 36.8
Treated and released, or left against medical advice 5,652 70.7 63.2 – 78.2
Abbreviations: ED, emergency department; IHEs, insulin-related hypoglycemia and errors.
a
Case counts and estimates from the National Electronic Injury Surveillance System - Cooperative Adverse Drug Event Surveillance (NEISS-
CADES) project, CDC. Refer to eTable 1 for definitions of case characteristics.
b
All insulin products reported in the ED medical record, including those implicated in IHEs and those listed as concomitant medications.
c
Categories are not mutually exclusive; therefore, percentages may total more than 100%.
d
Clinician documentation of error in insulin use (n=323), “insulin overdose” (n=6), or “insulin reaction” (n=11) with no documentation of 
hypoglycemia.
e
Discharge disposition missing for one case.
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Table 4
Number of Cases and Estimates of Precipitating Factors Identified in Emergency Department Visits for 
Insulin-related Hypoglycemia and Errors—United States, 2007–2011a
Precipitating Factors






Meal-related misadventure 952 45.9 38.2 – 53.6 • Unrestrained 19 YOF driver hit tree & brick wall. Blood 
sugar was 24. Took insulin 2 hours ago, but no time to 
eat. Diagnosis: Scalp abrasion, hypoglycemia.
• 75 YOM is an insulin-dependent diabetic, had a syncopal 
episode at home, found with blood sugar in the 20's by 
paramedics. EMS gave patient an amp of D50 IV. Per 
wife, patient has been having low blood sugar & it has 
been difficult to keep elevated. She feels it is due to 
chemo, possibly not eating enough. Diagnosis: 
Hypoglycemia.
Unintentionally took wrong 
insulin product
332 22.1 17.2 – 26.9 • 51 YOM, per spouse she injected patient with 50 units of 
NovoLog instead of 50 units of Lantus, blood glucose 33 
at time of arrival. Diagnosis: Hypoglycemia.
• 67 YOM accidentally took wrong medication. Confused 
Humalog insulin with Humulin insulin, blood sugar 36. 
Diagnosis: Hypoglycemia.
Unintentionally took wrong 
dose / Confused units
205 12.2 9.2 – 15.2 • Patient started new insulin regimen, 30–35 units of 
Lantus, 3–6 units of NovoLog, patient took 35 units of 
NovoLog accidentally, Blood sugar 40. Diagnosis: Insulin 
OD.
• 62 YOM given 40 units of regular insulin instead of 4, 




113 6.0 4.4 – 7.6 • 69 YOM hypoglycemic--patient's blood sugar was over 
400; took 12 units insulin in addition to his insulin pump--
Blood sugar dropped to 38; found unresponsive by wife. 
Diagnosis: Insulin shock.
Pump-related misadventure 38 1.5 0.7 – 2.2 • 33 YOF accidentally gave self bolus of 36 units regular 
insulin while changing insulin pump. Diagnosis: 
Overdose, accidental.
• 27 YOM is an insulin-dependent diabetic on insulin 
pump, had a witnessed tonoclonic seizure, EMS found 
blood sugar of 20. Patient admitted that he had eaten 
dinner but his pump had run out so he gave himself an 
injection & feels he may have overcompensated. 
Diagnosis: Hypoglycemia, seizure.
Other misadventurec 211 13.4 10.4 – 16.4 • 76 YOM with syncopal episode after mowing lawn for 3 
hours; took usual insulin at noon rather than AM--passed 
out. Diagnosis: Hypoglycemic reaction.
Abbreviations: ED, emergency department; EMS, emergency medical services; IHEs, insulin-related hypoglycemia and errors.
a
Case counts and estimates from the National Electronic Injury Surveillance System - Cooperative Adverse Drug Event Surveillance (NEISS-
CADES) project, CDC. Percentages are out of a total of 1,829 cases (20,346 estimated ED visits) where a precipitating factor was documented. 
Refer to eTable 1 for definitions of precipitating factors. Categories are not mutually exclusive; therefore, percentages may total more than 100%.
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b
Case descriptions are verbatim excerpts as reported by medical coders based on review of ED medical record narrative (with spelling corrected 
and abbreviations spelled out).
c
"Other misadventure" includes: insulin administration at the incorrect time or without regard to checking blood glucose, administration of "too 
much insulin" not further described, or medication error with insulin not otherwise specified.
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